These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17546719)

  • 1. Synthetic vaccines of tumor-associated glycopeptide antigens by immune-compatible thioether linkage to bovine serum albumin.
    Wittrock S; Becker T; Kunz H
    Angew Chem Int Ed Engl; 2007; 46(27):5226-30. PubMed ID: 17546719
    [No Abstract]   [Full Text] [Related]  

  • 2. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin.
    Dziadek S; Kowalczyk D; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7624-30. PubMed ID: 16247814
    [No Abstract]   [Full Text] [Related]  

  • 4. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
    Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.
    Renaudet O; BenMohamed L; Dasgupta G; Bettahi I; Dumy P
    ChemMedChem; 2008 May; 3(5):737-41. PubMed ID: 18205167
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthetic vaccines from tumor-associated glycopeptide antigens.
    Westerlind U; Kunz H
    Chimia (Aarau); 2011; 65(1-2):30-4. PubMed ID: 21469441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of a glycopeptide vaccine conjugate for induction of antibodies recognizing O-mannosyl glycopeptides.
    Yu J; Westerlind U
    Chembiochem; 2014 May; 15(7):939-45. PubMed ID: 24753400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response.
    Cai H; Huang ZH; Shi L; Sun ZY; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2012 Feb; 51(7):1719-23. PubMed ID: 22247051
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen.
    Buskas T; Ingale S; Boons GJ
    Angew Chem Int Ed Engl; 2005 Sep; 44(37):5985-8. PubMed ID: 16108081
    [No Abstract]   [Full Text] [Related]  

  • 14. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
    Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
    Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
    Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.
    Hoffmann-Röder A; Kaiser A; Wagner S; Gaidzik N; Kowalczyk D; Westerlind U; Gerlitzki B; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2010 Nov; 49(45):8498-503. PubMed ID: 20878823
    [No Abstract]   [Full Text] [Related]  

  • 18. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
    Glaffig M; Palitzsch B; Hartmann S; Schüll C; Nuhn L; Gerlitzki B; Schmitt E; Frey H; Kunz H
    Chemistry; 2014 Apr; 20(15):4232-6. PubMed ID: 24623572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
    Glaffig M; Stergiou N; Schmitt E; Kunz H
    ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue vaccines for cancer.
    Suckow MA; Heinrich J; Rosen ED
    Expert Rev Vaccines; 2007 Dec; 6(6):925-37. PubMed ID: 18377356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.